Royal London Asset Management Ltd. Trims Stake in Genmab A/S (NASDAQ:GMAB)

Royal London Asset Management Ltd. decreased its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 77.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,849 shares of the company's stock after selling 175,556 shares during the period. Royal London Asset Management Ltd.'s holdings in Genmab A/S were worth $1,253,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its stake in shares of Genmab A/S by 137.7% in the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company's stock worth $28,000 after acquiring an additional 544 shares during the period. Envestnet Portfolio Solutions Inc. boosted its stake in Genmab A/S by 2.3% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company's stock valued at $830,000 after buying an additional 633 shares during the last quarter. GAMMA Investing LLC boosted its stake in Genmab A/S by 194.0% during the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company's stock valued at $34,000 after buying an additional 749 shares during the last quarter. Grandfield & Dodd LLC boosted its stake in Genmab A/S by 3.4% during the first quarter. Grandfield & Dodd LLC now owns 26,418 shares of the company's stock valued at $790,000 after buying an additional 860 shares during the last quarter. Finally, Gallacher Capital Management LLC boosted its stake in Genmab A/S by 17.9% during the first quarter. Gallacher Capital Management LLC now owns 7,865 shares of the company's stock valued at $235,000 after buying an additional 1,192 shares during the last quarter. Institutional investors own 7.07% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Royal Bank of Canada raised Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. BTIG Research increased their price target on Genmab A/S from $46.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, June 27th. Truist Financial decreased their price objective on Genmab A/S from $53.00 to $50.00 and set a "buy" rating on the stock in a research report on Monday, September 9th. Finally, HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Friday. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $45.20.

Genmab A/S Trading Up 1.5 %

Shares of NASDAQ GMAB traded up $0.41 during midday trading on Friday, hitting $26.90. The company's stock had a trading volume of 506,451 shares, compared to its average volume of 572,483. The business's 50 day moving average is $27.25 and its two-hundred day moving average is $28.06. Genmab A/S has a 12-month low of $24.53 and a 12-month high of $38.80. The firm has a market cap of $17.79 billion, a P/E ratio of 22.42, a price-to-earnings-growth ratio of 0.81 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million during the quarter, compared to analysts' expectations of $734.60 million. On average, analysts predict that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.